January 16, 2018
BioVie (OTCQB: BIVI), reviewed key milestones achieved over the past year and provided a general update on the progress of...
December 11, 2017
BioVie announced the FDA granted the company a fast track designation for their orphan drug candidate BIV201.
September 28, 2017
BioVie reported the dosing for the first patient in its phase 2a clinical trial of BIV201 for the treatment of...
September 14, 2017
BioVie confirmed enrollment of the first patient in the Company's mid-stage clinical trial of BIV201.
August 29, 2017
BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
July 26, 2017
BioVie filed an application for patent coverage of their new drug candidate BIV201 in Japan.
May 24, 2017
BioVie received clearance from the US Patent and Trademark Office regarding the company's new drug candidate treating patients with advanced...